Development and clinical outcomes of pharmacist-managed diabetes care clinics

American Journal of Health-System Pharmacy

Volumn 63, Issue 14, 2006, Pages 1325-1331

  Morello, Candis M ^a   Zadvorny, Emily B ^b,c   Cording, Margaret A ^d,e   Suemoto, Ryan T ^d,f   Skog, Jilian ^g   Harari, Amir ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NMCSD Department of Internal Medicine   (United States)

^e WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^f W University College of Pharmacy   (United States)

^g SCRIPPS MERCY HOSPITAL   (United States)

^h USS Peleliu ^*

Author keywords

Ambulatory care; Clinical pharmacists; Diabetes mellitus; Interventions; Pharmaceutical services

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PHARMACIST; PRIORITY JOURNAL; RETINA; SCREENING TEST;

EID: 33746333865     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050430     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. National diabetes fact sheet. General information and national estimates on diabetes in the United States, 2005. www.cdc.gov/diabetes/pubs/factsheet05.htm (accessed 2006 Apr 12).
2. Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001; 24:1936-40.
3. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047-53.
4. Hogan P, Dall T, Nikolov P, for the American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003; 26:917-32.
5. Wagner EH, Sandhu N, Newton KM et al. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001; 285:182-9.
6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
7. [ Erratum, Lancet. 1999; 354:602. ]
8. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65.
9. [Erratum, Lancet. 1998; 352:1558.]
10. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-11.
11. Knowler WC, Barrett-Connor E, Fowler SE et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393-403.
12. American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care. 2000; 23(suppl 1):S1-116.
13. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157:2413-46.
14. [Erratum, Arch Intern Med. 1998; 158:573.]
15. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994; 89:1333-445.
16. American Association of Clinical Endocrinologists. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract. 2000; 6(2):163-213.
17. Morello CM, Suemoto RT. Diabetes. In: Blair MM, Blake EW, Harris IM, eds. Ambulatory care survival guide. Kansas City, MO: American College of Clinical Pharmacy; 2004:125-30.
18. National Committee for Quality Assurance. The state of health care quality: 2004. www.ncqa.org/communications/SOMC/SOHC2004.pdf (accessed 2006 Apr 12).
19. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
20. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005; 28(suppl 1):S4-36.
21. [Erratum, Diabetes Care. 2005; 28:990.]
22. Garrett DG, Bluml BM. Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005; 45:130-7.
23. Leal S, Glover JJ, Herrier RN et al. Improving quality of care in diabetes through a comprehensive pharmacist-based disease management program. Diabetes Care. 2004; 27:2983-4.
24. Irons BK, Lenz RJ, Anderson SL et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002; 22:1294-300.
25. Cioffi ST, Caron MF, Kalus JS et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004; 38:771-5.
26. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003; 43:149-59.